{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T13:12:53Z","timestamp":1783861973834,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.critrevonc.2025.104806","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T19:36:46Z","timestamp":1749843406000},"page":"104806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Comparison of third-generation tyrosine kinase inhibitor (TKI) ponatinib with first- and second-generation TKIs for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and bias-corrected meta-analysis"],"prefix":"10.1016","volume":"213","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3808-5991","authenticated-orcid":false,"given":"Muhammad Zain","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzaifa Fayyaz","family":"Khwaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Muhammad Ehsan","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Zulnorain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musab","family":"Maqsood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Ahmad","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Omais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104806_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-023-00891-x","article-title":"Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events","volume":"13","author":"Abdelmagid","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104806_bib2","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/ajh.25648","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors","volume":"94","author":"Abou Dalle","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104806_bib3","article-title":"Dasatinib in chronic myeloid leukemia: a review","author":"Aguilera","year":"2009","journal-title":"Ther. Clin. Risk Manag"},{"key":"10.1016\/j.critrevonc.2025.104806_bib4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An","year":"2010","journal-title":"Leuk. Res"},{"key":"10.1016\/j.critrevonc.2025.104806_bib5","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-188188","article-title":"Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation","volume":"142","author":"Badar","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104806_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00054","article-title":"Current concepts in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"4","author":"Bernt","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104806_bib7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104806_bib8","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.3324\/haematol.2016.159988","article-title":"BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors","volume":"102","author":"Byun","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104806_bib9","article-title":"Ponatinib: an update on its drug targets, therapeutic potential and safety","volume":"1878","author":"Gao","year":"2023","journal-title":"Biochim. Biophys. Acta BBA Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104806_bib10","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Glei\u00dfner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104806_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.bja.2019.08.015","article-title":"Use of the GRADE approach in systematic reviews and guidelines","volume":"123","author":"Granholm","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.critrevonc.2025.104806_bib12","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood.V128.22.1883.1883","article-title":"Ponatinib exerts multiple effects on vascular endothelial cells: possible mechanisms and explanations for the adverse vascular events seen in CML patients treated with ponatinib","volume":"128","author":"Hadzijusufovic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104806_bib13","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/s41409-020-01173-x","article-title":"Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation\u2014a registry study on behalf of the EBMT Acute Leukemia Working Party","volume":"56","author":"Hirschb\u00fchl","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.critrevonc.2025.104806_bib14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2018.02.010","article-title":"Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed philadelphia-positive acute lymphoblastic leukemia","volume":"18","author":"Jabbour","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104806_bib15","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2025.104806_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-115325","article-title":"Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI)","volume":"132","author":"Jabbour","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104806_bib17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4103\/CRST.CRST_98_19","article-title":"Ponatinib: a drug review","volume":"2","author":"Jain","year":"2019","journal-title":"Cancer Res Stat. Treat."},{"key":"10.1016\/j.critrevonc.2025.104806_bib18","doi-asserted-by":"crossref","unstructured":"Jones D., Thomas D., Yin C.C., O\u2019Brien S., Cortes J.E., Jabbour E., et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors n.d. https:\/\/doi.org\/10.1002\/cncr.23666.","DOI":"10.1002\/cncr.23666"},{"key":"10.1016\/j.critrevonc.2025.104806_bib19","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1007\/s00432-022-04316-3","article-title":"Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects","volume":"149","author":"Liu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104806_bib20","article-title":"Resistant mutations in CML and Ph+ALL \u2013 role of ponatinib","author":"Miller","year":"2014","journal-title":"Biol. Targets Ther."},{"key":"10.1016\/j.critrevonc.2025.104806_bib21","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3390\/cancers13071643","article-title":"Meta-analysis of gastrointestinal adverse events from tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"13","author":"Mohanavelu","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104806_bib22","doi-asserted-by":"crossref","unstructured":"Nicolini F.E., Basak G.W., Kim D.-W., Olavarria E., Pinilla-Ibarz J., Apperley J.F., et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation n.d. https:\/\/doi.org\/10.1002\/cncr.30558.","DOI":"10.1002\/cncr.30558"},{"key":"10.1016\/j.critrevonc.2025.104806_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104806_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/hematology.2020000108","article-title":"First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?","volume":"2020","author":"Oehler","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.critrevonc.2025.104806_bib25","doi-asserted-by":"crossref","unstructured":"Onida F., Ball G., Kantarjian H.M., Smith T.L., Glassman A., Albitar M., et al. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia n.d. https:\/\/doi.org\/10.1002\/cncr.10832.","DOI":"10.1002\/cncr.10832"},{"key":"10.1016\/j.critrevonc.2025.104806_bib26","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/ajh.27378","article-title":"Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"99","author":"Othman","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104806_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106885","article-title":"Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center","volume":"119","author":"Othman","year":"2022","journal-title":"Leuk. Res."},{"key":"10.1016\/j.critrevonc.2025.104806_bib28","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia","author":"Pavlovsky","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2025.104806_bib29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome\u2013positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104806_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","article-title":"Imatinib and beyond\u2014exploring the full potential of targeted therapy for CML","volume":"6","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104806_bib31","author":"Raza","year":"2025","journal-title":"Comparison of Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib with First- and Second-Generation TKIs for Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Systematic Review and Bias-Corrected Meta-analysis"},{"key":"10.1016\/j.critrevonc.2025.104806_bib32","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1007\/s12325-023-02497-y","article-title":"Ponatinib vs. imatinib as frontline treatment for philadelphia chromosome-positive acute lymphoblastic leukemia: a matching adjusted indirect comparison","volume":"40","author":"Ribera","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.critrevonc.2025.104806_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2020.10.013","article-title":"Compared to randomized studies, observational studies may overestimate the effectiveness of DOACs: a metaepidemiological approach","volume":"130","author":"Safieddine","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2025.104806_bib34","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104806_bib35","article-title":"Prognostic Factors For Progression In Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs)","volume":"134","author":"Sasaki","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104806_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-188118","article-title":"Consolidation with ponatinib plus sequential blinatumomab and chemotherapy after low intensity dasatinib-based induction in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: outcomes from a single institution","volume":"142","author":"Schwartz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104806_bib37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24625","article-title":"Poor outcomes associated with +der(22)t(9;22) and \u22129\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor","volume":"92","author":"Short","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104806_bib38","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2012-07-442871","article-title":"Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD","volume":"121","author":"Smith","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104806_bib39","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104806_bib40","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104806_bib41","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/bimj.201900376","article-title":"A bias-corrected meta-analysis model for combining, studies of different types and quality","volume":"63","author":"Verde","year":"2021","journal-title":"Biom. J."},{"key":"10.1016\/j.critrevonc.2025.104806_bib42","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/sj.leu.2402770","article-title":"Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)","volume":"16","author":"Wassmann","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.104806_bib43","article-title":"Comparative efficacy and safety of different doses of ponatinib versus other tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia: a systematic review and network meta-analysis","author":"Zhang","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.critrevonc.2025.104806_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231165866","article-title":"Comparison of the efficacy and safety of ponatinib and dasatinib in philadelphia chromosome-positive acute lymphoblastic leukemia with central nervous system relapse: a retrospective study","volume":"22","author":"Zhu","year":"2023","journal-title":"Technol. Cancer Res. Treat."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001945?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001945?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:27:44Z","timestamp":1762352864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":44,"alternative-id":["S1040842825001945"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104806","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of third-generation tyrosine kinase inhibitor (TKI) ponatinib with first- and second-generation TKIs for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: A systematic review and bias-corrected meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104806"}}